HYPERTENSION AND THE GUT MICROBIOME: USING GUT MICROBES TO REDUCE BLOOD PRESSURE
Professor Francine Marques
Professor of Genetics and Genomics
Monash University, Victoria, Australia
RESEARCHER PROFILE (Filmed in Clayton, Victoria | December 2024)
Professor Francine Marques is an National Health and Medical Research Council Emerging Leader, Viertel Charitable Foundation, and National Heart Foundation Fellow.
She leads the Hypertension Research Laboratory at Monash University and has published more than 120 peer-reviewed papers in journals such as Nature Reviews Cardiology, Nature Medicine, Nature Cardiovascular Research, and Circulation.
As a researcher Professor Marques has secured over $10 million in competitive funding as a principal investigator. She has won 31 awards, including the 2019 American Heart Association Hypertension Council Goldblatt Award, the 2020 High Blood Pressure Research Council of Australia and 2021 International Society of Hypertension Mid-Career Awards, the 2021 Australian Academy of Science Gottschalk Medal, and the 2024 Australian Society of Medical Research Peter Doherty Leading Light Award, and was a finalist for 12 awards, including the Eureka Prize Emerging Leader in Science.
Her research team aims to build exceptional scientists that help improve cardiovascular health, using translational approaches to lower blood pressure via the gut microbiome. Professor Marques is also passionate about equity, diversity and inclusion (EDI) and helping communities change the current culture of research.
She has led research identifying intrinsic equity issues in the cardiovascular research community in Australia (https://pubmed.ncbi.nlm.nih.gov/32839116/), followed by research to find solutions for these issues (https://pubmed.ncbi.nlm.nih.gov/35577952/), resulting in the 2021 Women’s Agenda Emerging Leader in STEM award.
Outside work, Francine enjoys baking, travelling, spending time with family, friends and her dogs, and reading books.
https://orcid.org/0000-0003-4920-9991
-
Novel immunotherapies in lymphoma
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
-
Liver cancer biomarkers, risk prediction & progression
Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.
